Author: Ravi Shankar

Planned $16 million facility at the Atlas Complex advances Callan JMB’s pharmaceutical manufacturing strategy and strengthens its role in U.S. healthcare supply-chain preparedness

SPRING BRANCH, Texas, Oct. 20, 2026 (GLOBE NEWSWIRE) — Callan JMB Inc. (NASDAQ: CJMB) (“Callan JMB” or the “Company”), a diversified preparedness, logistics, and critical-infrastructure company, today announced formal approval of blueprints for the planned $16 million intravenous (IV) bag manufacturing and distribution facility at the Atlas Complex in Marion, Alabama. Once in production, the facility is projected to generate $450 million in annual revenue, including $300 million from standard IV bags and $150 million from premixed drug IV bags.

The facility is planned within the Marion 9 Biomanufacturing Center at the Atlas Complex and demonstrates Callan JMB’s previously announced pharmaceutical manufacturing initiative with Alabama State University. The blueprint approval significantly advances the project and provides the design basis for completing a successful facility by combining automated production with quality-control and advanced distribution capabilities.

“The commercial objective is clear: build improved domestic manufacturing capacity for essential IV products and support it with the logistics, quality controls, and distribution capabilities needed to serve healthcare customers,” said Wayne Williams, Callan JMB’s Chief Executive Officer. “Approving the blueprints is a concrete step toward that objective. This project builds on our healthcare logistics and emergency-preparedness experience while supporting the strengthening of the United States (U.S.) domestic pharmaceutical production, enhancing U.S. supply chain resilience, and improving national security through medical preparedness.”

The facility is designed to incorporate automation and robotics to support manufacturing efficiency, consistent production processes, and quality assurance. Integrating production with distribution capabilities is expected to streamline coordination across manufacturing, storage, and delivery of essential healthcare products.

For Callan JMB, the project extends its role in healthcare supply chains by supporting domestic pharmaceutical manufacturing. The Company’s logistics, monitoring, regulatory-compliance, and operational capabilities are intended to help connect production at Atlas with the healthcare organizations and other customers that rely on these products.

The planned IV bag manufacturing capacity also supports Callan JMB’s broader emergency-preparedness strategy. A domestic source of IV products, supported by coordinated warehousing and distribution, helps strengthen supply continuity for healthcare providers during routine operations and periods of heightened demand or disruption.

Through its collaboration with Alabama State University, the initiative is also expected to support important workforce development and increase research partnership agreements that can help meet the technical and operational requirements of pharmaceutical manufacturing. The planned investment would expand advanced manufacturing activity in Marion and create new opportunities for skilled employment in Perry County and the surrounding region.

About Callan JMB Inc.

Callan JMB Inc. (NASDAQ: CJMB) is a diversified logistics, preparedness, and critical-infrastructure company supporting healthcare organizations, government agencies, and commercial partners. The Company provides fulfillment, warehousing, cold-chain logistics, monitoring, regulatory compliance, specialty packaging, and emergency-preparedness services designed to protect critical products, strengthen supply chains, and support continuity of operations. Through its businesses and strategic partnerships, Callan JMB is building a broader platform spanning healthcare and pharmaceutical logistics, domestic manufacturing, and critical electrical infrastructure. For more information, visit www.callanjmb.com.

Investor Contact

Valter Pinto, Managing Director
KCSA Strategic Communications
CallanJMB@kcsa.com
212.896.1254

Media Contact

Arian Hopkins
ahopkins@callanjmb.com

About the Atlas Complex by Callan JMB

Atlas Complex by Callan JMB is a pharmaceutical, medical, and logistics campus located in Marion, Alabama. Designed to support U.S. pharmaceutical onshoring and strengthen domestic supply chains, the campus provides scalable infrastructure for pharmaceutical manufacturing, quality assurance and quality control (QA/QC), research collaboration, workforce development, cold chain logistics, and domestic distribution within a single integrated environment.

Atlas Complex Media Contact
Arian Hopkins
ahopkins@callanjmb.com

Forward-Looking Statement

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by, or that otherwise include the words “believe,” “anticipate,” “estimate,” “expect,” “intend,” “plan,” “project,” “prospects,” “outlook,” and similar words or expressions, or future or conditional verbs, such as “will,” “should,” “would,” “may,” and “could,” are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the Company’s actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company’s forward-looking statements, please see the Company’s Registration Statement Under the Securities Act of 1933 on Form S-1, including but not limited to the discussion under “Risk Factors” therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

CONSHOHOCKEN, Pa., Oct. 20, 2026 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its third-quarter 2026 financial results on Tuesday, November 3, 2026, prior to the open of the U.S. financial markets.

Following the announcement, Madrigal’s management will host a live webcast at 8 a.m. Eastern Time to review the Company’s financial and operating results.

The live webcast may be accessed at the Investor Relations section of the Madrigal Pharmaceuticals website. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

The webcast will be available approximately two hours after the live webcast.

About Madrigal
Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra was the first medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

VANCOUVER, British Columbia, Oct. 20, 2026 (GLOBE NEWSWIRE) — Riverside Resources Inc. (“Riverside” or the “Company“) (TSX-V: RRI) (OTCQB: RVSDF) (FSE: 5YY0), is pleased to announce that its subsidiary, Ravena Resources Corp. (“Ravena“), together with RRM Exploraciones, S.A.P.I. DE C.V., has completed an option agreement with 1559239 B.C. Ltd., operating as Calu Resources Corp (“Calu“) for the Cecilia Project in Sonora, Mexico. Under the agreement, Calu can earn 100% interest in the project by completing the business terms outlined below with a total earn-in work expenditure of $6,650,000. Ravena, the subsidiary of Riverside, will manage the exploration work and receive a 10% operations fee. The work will include an updated NI 43-101 report, followed by a firm commitment exploration program of at least C$150,000 in the first 12 months. Calu has made the initial payment of C$50,000 to Ravena to begin the option commitment. Calu is a new private company that intends to become public through a three-way amalgamation with Pender Capital. That transaction is described in a separate news release issued by Calu and Pender Street Capital Corp.

“Riverside is pleased to progress another property in its portfolio where Riverside retains a 2% NSR royalty and its subsidiary, Ravena Resources, receives option payments and acts as the operator of the exploration program,” said John-Mark Staude, CEO of Riverside Resources. “As we build our royalty portfolio, we are focusing on properties where discovery can add value to those royalties, particularly properties held through Riverside and, going forward, those included in the planned 2027 spin-out of Ravena Resources Corp. With more than C$6,500,000 in exploration expenditures under the earn-in, this agreement allows Cecilia to advance at no cost to Riverside.”

Option and Earn-In Terms

Under the Option Agreement, Calu may acquire a 100% interest in the Cecilia Project by making aggregate cash and share payments of C$1,200,000 and funding aggregate exploration expenditures of C$6,650,000 over five years, as follows:

Due Date	Payments		Cumulative Exploration Expenditures
Effective date of Option Agreement	$50,000 in cash		Nil
First anniversary	$150,000 in cash or Calu shares		$150,000
Second anniversary	$150,000 in cash or Calu shares		$500,000
Third anniversary	$150,000 in cash or Calu shares		$2,000,000
Fourth anniversary	$200,000 in cash or Calu shares		$2,000,000
Fifth anniversary	$500,000 in cash		$2,000,000
Total:	$1,200,000		$6,650,000

Unless otherwise indicated, all amounts in this news release are expressed in Canadian dollars.

The initial C$50,000 cash payment and at least C$150,000 in exploration expenditures during the first 12 months are firm commitments of Calu under the Option Agreement. All remaining payments and exploration expenditures are optional, but Calu must complete them to keep the option in good standing and to exercise it.

Where permitted under the option agreement, Calu may elect, with at least 10 business days’ notice, to make all or part of a cash payment in Calu shares. The number of shares issued will be based on the 10-trading-day volume-weighted average price of Calu shares on a recognized stock exchange, subject to applicable securities laws and stock exchange policies. Shares will be issued fully paid and free of encumbrances, other than statutory resale restrictions.

Ravena will act as operator of all exploration programs on the Cecilia Project during the option period and will be entitled to a management fee equal to 10% of eligible exploration expenditures.

The Cecilia Project is subject to an existing 2.0% net smelter returns royalty in favour of 1412597 B.C. Ltd., a subsidiary of Riverside Resources Inc. Upon exercise of the option, Calu will grant Ravena an additional 0.5% net smelter returns royalty. Calu will have the right to purchase the entire 0.5% royalty from Ravena for US$1,500,000 in cash at any time prior to January 1, 2035.

Cecilia Project

The Cecilia Project is located in northeastern Sonora, Mexico, approximately 40 kilometres southwest of Agua Prieta, near the Mexico-United States border, and 100km due east of the Cananea large copper mining complex. Operations of Couer Mining, First Majestic, Agnico Eagle, Grupo Mexico, Penoles, Hylander Silver are all active in the area around the Project. Riverside’s exploration work has included drilling at four key targets that warrant follow-up exploration. Six additional targets are permitted for drilling and could host a new discovery as well. If exploration is successful, Riverside will benefit through its royalty interests in addition to the option payments. The main concession block includes the Cecilia 1 titled claim and collectively covers > 60 km² of titled ground plus an additional 16 km² of application ground for a total property area of approximately 7,583 hectares (76 km²). Further information about the property has been provided previously and is available on the Riverside website.

Northern Miner Interview

John-Mark Staude, President and CEO of Riverside, and Julian Manco, Vice President of Exploration for Ravena Resources, discuss the planned Ravena spin-out with The Northern Miner in a sponsored video interview recorded at the Precious Metals Summit: https://www.northernminer.com/stock-markets-investing/sponsored-riverside-readies-mexico-spinout/1003895457/.

Corporate News – Options Grant

On September 4, 2026 the Company granted incentive stock options to purchase an aggregate of 1,650,000 common shares of the Company to certain directors, officers, employees and consultants of the Company, in accordance with the Company’s Stock Option Plan. The options are exercisable at a price of $0.41 per share for a period of five years, expiring September 4, 2031. Options granted to Director’s vest in three equal installments of 33% on the six-month, twelve month and eighteen-month anniversaries. Options granted to certain officers, employees and consultants vest in four equal installments of 25% of the common shares on the three-month, six-month, nine-month and twelve-month anniversaries. The grant is subject to the policies of the TSX Venture Exchange.

Qualified Person & QA/QC

The scientific and technical data contained in this news release pertaining to the Project was reviewed and approved by Julian Manco, P.Geo, a non-independent qualified person to Riverside Resources Inc., who is responsible for ensuring that the information provided in this news release is accurate and who acts as a “qualified person” under National Instrument 43-101 Standards of Disclosure for Mineral Projects.

About Riverside Resources Inc.

Riverside is a well-funded exploration company driven by value generation and discovery. The Company has a solid balance sheet with no debt and fewer than 95M shares outstanding with a strong portfolio of gold-silver and copper assets and royalties in North America. Riverside has extensive experience and knowledge operating in Mexico and Canada and leverages its large database to generate a portfolio of prospective mineral properties. Riverside has properties available for option, with information available on the Company’s website at www.rivres.com. 

ON BEHALF OF RIVERSIDE RESOURCES INC.

“John-Mark Staude”

Dr. John-Mark Staude, President & CEO

For additional information contact:

John-Mark Staude President, CEO Riverside Resources Inc. info@rivres.com Phone: (778) 327-6671 Fax: (778) 327-6675 Web: www.rivres.com

Eric Negraeff Corporate Communications Riverside Resources Inc. Eric@rivres.com Phone: (778) 327-6671 TF: (877) RIV-RES1 Web: www.rivres.com

Certain statements in this press release may be considered forward-looking information, including statements regarding the Option Agreement, the planned exploration program, and payments and exploration expenditures to be made by Calu. These statements can be identified by the use of forward-looking terminology (e.g., “expects”, “estimates”, “intends”, “anticipates”, “believes”, “plans”). Such information involves known and unknown risks, including the risk that Calu does not complete the payments and exploration expenditures required under the Option Agreement, the risk that Calu’s proposed amalgamation with Pender Capital is not completed as contemplated, or at all, the value of any Calu shares issued as payment, availability of funds, the results of financing and exploration activities, the interpretation of exploration results and other geological data, unanticipated costs and expenses, and other risks identified by Riverside in its public securities filings, that may cause actual events to differ materially from current expectations. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Foldable bicycle pioneer replaces a 12-year-old custom trade system as it invests in its global network of retail partners

AUSTIN, Texas and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) — Commerce.com (Nasdaq: CMRC), the open commerce ecosystem built to help merchants win as AI reshapes how customers discover and buy, today announced that Brompton, the British foldable bicycle manufacturer, has launched its new Brompton Partner Portal on BigCommerce B2B Edition.

The portal gives Brompton’s global network of independent retailers a modern ordering experience and runs on the same BigCommerce instance and product catalog that powers the company’s direct-to-consumer business.

Brompton first launched its composable direct-to-consumer site on BigCommerce in 2024. The new partner portal extends that foundation to the wholesale side of the business, which accounts for roughly 75% of Brompton’s total sales across over 1,000 retail partners worldwide.

“Our retail partners are central to Brompton’s success. The new Partner Portal gives them a modern, intuitive way to explore our product range, place orders and access the information they need to support our joint customers,” said Oliver Boardman, CTO at Brompton. “This investment is about making it easier for our partners to do business with Brompton and grow alongside us.”

Retiring a decade-old bespoke platform

Brompton’s previous wholesale system was created more than a decade ago and was designed around the company’s highly configurable bicycles. As Brompton’s range expanded to include electric, titanium and large-wheel bikes, the breadth of products, options and content available to partners grew significantly.

The new Partner Portal provides a richer product experience, with clearer imagery, improved product information and curated catalogues that make it easier for partners to understand and access the full Brompton range, while also providing a more scalable foundation for future growth. Over time, Brompton plans to increase the range of tools it provides in the system to support its partners’ businesses.

Four months to launch with an in-house, AI-accelerated team

Where Brompton’s original DTC project took about a year to reach its first market, the company’s internal project team built and launched the partner portal in four months, leveraging its BigCommerce platform knowledge from the B2C site.

“This wasn’t just a technology project. It was delivered through close collaboration between teams across Brompton, combining deep knowledge of our products, partners and processes with the technical expertise to bring it all together. AI tools helped accelerate delivery, but the real success came from having engaged people across the business working towards a shared goal,” said Boardman. “That collaboration, combined with the knowledge we’ve built on the BigCommerce platform, allowed us to launch significantly faster while continuing to build our internal capabilities.”

A market-by-market rollout

The Partner Portal is live in Germany and Austria, with the remaining European markets and the UK to follow this month. Additional localization work for the U.S., Japan, China and Singapore is underway, with the full rollout targeted for completion ahead of the spring.

“Historically we had different systems for different things,” said Boardman. “We want to bring it all together so there’s a single place partners can come to interact with the brand. If we make it as easy as possible for people to work with us, that helps them give our customers a great experience.”

“For years, manufacturers put their digital investment into direct-to-consumer while their dealers made do with ordering tools no shopper would tolerate,” said Lance Owide, vice president of B2B product management at Commerce. “That gap is common across manufacturing, but it’s closing fast. Brompton deserves credit for recognizing the need to serve consumers and partners from one platform, one catalog and one team.”

Brompton joins a growing group of cycling and outdoor brands on the BigCommerce platform. See more here: https://www.bigcommerce.com/case-study/?industries=sports-%26-outdoors

Learn more about how BigCommerce supports B2B businesses: https://www.bigcommerce.com/solutions/b2b-ecommerce-platform/

About Commerce
Commerce (Nasdaq: CMRC) empowers businesses to innovate, grow, and thrive by providing an open, AI-driven commerce ecosystem. As the parent company of BigCommerce, Feedonomics, and Makeswift, Commerce connects the tools and systems that power growth, enabling businesses to unlock the full potential of their data, deliver seamless and personalized experiences across every channel, and adapt swiftly to an ever-changing market. Trusted by leading businesses like Coldwater Creek, Cole Haan, Dell, Harvey Nichols, King Arthur Baking Co., Mizuno, Pacsun, Perry Ellis, Skechers, SportsShoes and Uplift Desk, Commerce delivers the storefront control, optimized data, and AI-ready tools businesses need to grow, serve diverse buyers, and operate with confidence in an increasingly intelligent, multi-surface world. For more information, visit www.commerce.com or follow us on X and LinkedIn.

BigCommerce®, the Commerce logo, and other brands are the trademarks or registered trademarks of Commerce.com Pty. Ltd. Third-party trademarks and service marks are the property of their respective owner.

Media Contact:
Brad Hem
pr@commerce.com

• In UC, duvakitug maintained high rates of clinical remission, clinical response, and endoscopic improvement at Week 44
• In CD, duvakitug maintained high rates of endoscopic response, clinical response, and clinical remission at Week 44
• Duvakitug was well tolerated and safety was consistent with the induction study

PARSIPPANY, N.J. and PARIS, Oct. 20, 2026 (GLOBE NEWSWIRE) — Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and Sanofi announced new positive data from the RELIEVE UCCD phase 2b long-term extension (LTE) study (clinical trial identifier: NCT05668013) in patients with moderately-to-severely active ulcerative colitis (UC) or Crohn’s disease (CD), which demonstrated that duvakitug maintained clinically meaningful efficacy improvements across multiple endpoints over 44 weeks. Duvakitug is an investigational human monoclonal antibody that targets TL1A, a protein that amplifies inflammation and potentially drives fibrosis in UC and CD.

In addition, biomarker findings that advance the understanding of how duvakitug may impact inflammation and tissue remodeling in inflammatory bowel disease (IBD) were shared. These data were presented today at United European Gastroenterology (UEG) Week 2026 in Barcelona.

The RELIEVE UCCD LTE study evaluated the efficacy, safety, and tolerability of duvakitug through 44 weeks of maintenance treatment after induction in patients with UC and CD, the two most common forms of IBD. Patients (n=130, 72 with UC and 58 with CD) who responded to duvakitug treatment in the 14-week induction study were randomized to receive either duvakitug 450 mg or 900 mg subcutaneously every four weeks (Q4W) for up to 58 weeks of total exposure.

UC Results
At Week 44, maintenance treatment with duvakitug demonstrated high rates of clinical remission and clinical response, as measured by the modified Mayo Score (mMS), meaning active UC symptoms such as rectal bleeding, increased stool frequency, and pain have stopped (remission) or improved (response). Duvakitug treatment also achieved high rates of endoscopic improvement, defined by a Mayo Endoscopic Score of 0 (inactive disease in the colon) or 1 (mild disease activity), which measures the presence and degree of intestinal inflammation. Efficacy outcomes were numerically higher at 900 mg compared to 450 mg, consistent with a dose response. 

Efficacy in UC at Week 44 Maintenance Phase Endpoint
	Duvakitug 450 mg Q4W [n=34]	Duvakitug 900 mg Q4W [n=38]
Clinical remission (mMS)	47% [95% CI: 30, 65]	58% [95% CI: 42, 73]
Clinical response (mMS)	82% [95% CI: 61, 91]	87% [95% CI: 71, 94]
Endoscopic improvement	59% [95% CI: 42, 76]	63% [95% CI: 47, 78]
Data are descriptive. Confidence intervals (CIs) are based on logistic regression.

“Ulcerative colitis can have a significant impact on patients that disrupts even the most basic daily activities. Despite available therapies, some patients continue to experience flares that impact their lives in various ways and may contribute to disease progression,” said Walter Reinisch, MD, PhD, Director of the Inflammatory Bowel Disease Study Group at the Medical University of Vienna and a co-lead investigator of the RELIEVE UCCD LTE study. “These results underscore the potential of duvakitug to deliver effective and durable relief from persistent inflammation and symptoms, supporting better long-term disease management in patients with ulcerative colitis.”

CD Results
Duvakitug maintenance treatment demonstrated high rates of endoscopic response, defined as a 50% or more decrease from baseline in Simple Endoscopic Score for Crohn’s Disease (SES-CD) at Week 44. SES-CD assesses mucosal ulcers, the ulcerated surface, the endoscopic extension, and the presence of stenosis in the colon as a gauge of disease severity. Additionally, duvakitug maintained high rates of clinical response and clinical remission as measured by the Crohn’s Disease Activity Index (CDAI), meaning symptoms such as abdominal pain, diarrhea, and fatigue have stopped (remission) or improved (response). Duvakitug appeared to demonstrate a dose response, with numerically higher efficacy results achieved at the higher dose. 

Efficacy in CD at Week 44 Maintenance Phase Endpoint
	Duvakitug 450 mg Q4W [n=27]	Duvakitug 900 mg Q4W [n=31]
Endoscopic response	41% [95% CI: 25, 62]	55% [95% CI: 39, 75]
Clinical response (CDAI)	81% [95% CI: 63, 94]	87% [95% CI: 70, 96]
Clinical remission (CDAI)	81% [95% CI: 65, 95]	84% [95% CI: 68, 96]
Data are descriptive. Confidence intervals (CIs) are based on logistic regression.

“Due to the heterogeneous nature of Crohn’s disease, many patients either stop responding or never respond to available therapies, leaving them with uncontrolled symptoms that cause physical distress,” said Vipul Jairath, MBChB, DPhil, FRCP, FRCPC, Professor of Medicine in the Departments of Medicine, Epidemiology and Biostatistics at Western University and a co-lead investigator of the RELIEVE UCCD LTE study. “The efficacy rates seen with duvakitug in the maintenance period highlight its potential as a new treatment option that could help more patients achieve sustained remission.”

Across both UC and CD, duvakitug was generally well tolerated throughout the maintenance period, with a safety profile consistent with the induction phase and no new safety concerns identified. The most frequently reported adverse events (AEs) occurring in ≥5% of patients across pooled duvakitug dose groups in UC were upper respiratory tract infection and nasopharyngitis, and in CD were upper respiratory tract infection, CD, hypertension, nasopharyngitis, anemia, and influenza. The majority of AEs were mild or moderate in severity. Discontinuation rates due to AEs were low (UC, 4% and 2% in the 450 mg and 900 mg arms, respectively, and in CD were 6% in each arm).

Biomarker Results
Biomarker analyses from the RELIEVE UCCD induction study (clinical trial identifier: NCT05499130) were presented at UEG Week 2026. Duvakitug reduced blood levels of markers connected to multiple inflammatory pathways in UC and to the Th17 and Th1 immune pathways in CD, as well as markers of neutrophilic inflammation in both blood and tissue in CD and UC. In patients with CD, duvakitug also reduced markers of tissue remodeling. These findings provide additional mechanistic evidence that TL1A inhibition may address both inflammation and, potentially, fibrosis.

Additionally, clinical results from the RELIEVE UCCD induction study were recently published in The Lancet Gastroenterology and Hepatology for UC and CD.

Duvakitug Clinical Development Program
Duvakitug is being investigated in the phase 3 SUNSCAPE-1 (clinical trial identifier: NCT07184996) and SUNSCAPE-2 (clinical trial identifier: NCT07185009) studies in moderately-to-severely active UC, and the phase 3 STARSCAPE-1 (clinical trial identifier: NCT07184931) and STARSCAPE-2 (clinical trial identifier: NCT07184944) studies in moderately-to-severely active CD. Sanofi and Teva have initiated the phase 2 AURALIGHT study (clinical trial identifier: NCT07812116) of duvakitug in moderate-to-severe hidradenitis suppurativa and are planning a phase 2 study of duvakitug in fibrostenotic Crohn’s disease.

Duvakitug is currently under clinical investigation, and its efficacy and safety have not been evaluated by any regulatory authority.

About IBD
Inflammatory bowel disease (IBD) is an autoimmune disorder characterized by chronic inflammation of the gastrointestinal (GI) tract. Globally, approximately 4.9 million cases of IBD have been identified, with incidence rising in several regions. The two main types of IBD are ulcerative colitis (UC) and Crohn’s disease (CD), which are characterized by repetitive cycles of relapses and remission. Common symptoms of both conditions include persistent diarrhea, rectal bleeding, abdominal pain, loss of appetite, and weight loss.

Prolonged inflammation can lead to damage within the GI tract, including fibrosis, a common complication of IBD characterized by an excessive accumulation of scar tissue in the intestinal wall, which may cause narrowing and obstruction.

Currently, there is no cure for IBD. The goal of current treatment is to induce and maintain remission and prevent flares.

About the RELIEVE UCCD phase 2b program
The RELIEVE UCCD program is comprised of an induction study and a long-term extension (LTE).

RELIEVE UCCD: A 14-week phase 2b, randomized, double-blinded, dose-ranging induction study to evaluate the efficacy, safety, pharmacokinetics, and tolerability of duvakitug in adults with moderate-to-severe ulcerative colitis (UC) or Crohn’s disease (CD). The study was an innovative and efficient basket study design allowing the inclusion of patients with either UC or CD. It is the first and only randomized, blinded and placebo-controlled phase 2 study to investigate the impact of TL1A inhibition in CD.

RELIEVE UCCD LTE: An ongoing phase 2b study to evaluate the long-term efficacy and safety of duvakitug. Patients who received duvakitug, completed the 14-week induction study, and were responders, entered a 44-week double-blind maintenance period and were re-randomized to receive either 450 mg or 900 mg of subcutaneous duvakitug every four weeks. Patients who completed the 44-week maintenance period may continue to receive duvakitug in an open-label extension.

Primary efficacy endpoints for both the 14-week induction study and the 44-week maintenance period are clinical remission (as defined by mMS) in the UC cohort or endoscopic response (as defined by SES-CD) in the CD cohort. The study includes sites in the US, Europe, Israel, and Asia.

About duvakitug 
Duvakitug is a human monoclonal antibody targeting tumor necrosis factor-like ligand 1A (TL1A) being developed to reduce inflammation and potentially fibrosis. Duvakitug is currently in phase 3 clinical studies for the treatment of ulcerative colitis and Crohn’s disease and is also being investigated in hidradenitis suppurativa and fibrostenotic Crohn’s disease. The safety and efficacy of duvakitug have not been reviewed by any regulatory authority.

About the Sanofi and Teva collaboration
Sanofi and Teva are collaborating to co-develop and co-commercialize duvakitug for the treatment of ulcerative colitis and Crohn’s disease, as well as fibrostenotic Crohn’s disease and hidradenitis suppurativa. Each company will equally share the development costs globally, and the net profits and losses in major markets, with other markets subject to a royalty arrangement. Teva will lead commercialization of the product in Europe, Israel, and specified other countries, and Sanofi will lead commercialization in North America, Japan, other parts of Asia, and the rest of the world.

About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is transforming into a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment to bettering health has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how, visit www.tevapharm.com.

Cautionary Note Regarding Forward-Looking Statements
This Press Release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop duvakitug for the treatment of ulcerative colitis (UC) and Crohn’s disease (CD) as well as fibrostenotic Crohn’s disease and hidradenitis suppurativa; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute on our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and to profitably commercialize our innovative medicines and biosimilar portfolio, whether organically or through business development; our significant indebtedness; our business and operations in general; compliance, regulatory and litigation matters; financial, economic and other risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2026 and in our Annual Report on Form 10-K for the year ended December 31, 2025, including in the sections captioned “Risk Factors” and “Forward-Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.

About Sanofi
Sanofi is an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. 

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Sanofi forward-looking statements
This press release contains forward-looking statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future events and economic performance. Words such as “expect,” “anticipate,” “believe,” “intend,” “estimate,” “plan,” “can,” “contemplate,” “could,” “is designed to,” “may,” “might,” “potential,” “objective,” “attempt,” “target,” “project,” “strategy,” “strive,” “desire,” “predict,” “forecast,” “ambition,” “guideline,” “seek,” “should,” “will,” “goal,”  or the negative of these, and similar expressions are intended to identify forward-looking statements. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the U.S. Food and Drug Administration or the European Medicines Agency, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates; the fact that product candidates if approved may not be commercially successful; unexpected regulatory actions or delays, or government regulation generally; authorities’ decisions regarding whether and when to approve a product candidate; political pressure in the United States to mandate lower drug prices including “most favored nation” pricing for State Medicaid programs; the future approval and commercial success of therapeutic alternatives; Sanofi’s ability to benefit from external growth opportunities, to complete related transactions and/or obtain regulatory clearances, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general; risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation;  trends in exchange rates and prevailing interest rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole.  The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the French Markets Authority (AMF) made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2025 or contained in our periodic reports on Form 6-K. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. Considering these risks, uncertainties, and assumptions, you should not place undue reliance on any forward-looking statements contained herein.

Teva Media Inquiries:
TevaCommunicationsNorthAmerica@tevapharm.com
Teva Investor Relations Inquiries:
TevaIR@Tevapharm.com

Sanofi Media Relations
Sandrine Guendoul | +33 6 25 09 14 25 | sandrine.guendoul@sanofi.com 
Evan Berland | +1 215 432 0234 | evan.berland@sanofi.com
Léo Le Bourhis | +33 6 75 06 43 81 | leo.lebourhis@sanofi.com
Victor Rouault | +33 6 70 93 71 40 | victor.rouault@sanofi.com 
Timothy Gilbert | +1 516 521 2929 | timothy.gilbert@sanofi.com 
Léa Ubaldi | +33 6 30 19 66 46 | lea.ubaldi@sanofi.com
Ekaterina Pesheva | +1 410 926 6780 | ekaterina.pesheva@sanofi.com 

Sanofi Investor Relations
Thomas Kudsk Larsen | +44 7545 513 693 | thomas.larsen@sanofi.com
Alizé Kaisserian | +33 6 47 04 12 11 | alize.kaisserian@sanofi.com 
Keita Browne | +1 781 249 1766 | keita.browne@sanofi.com 
Nathalie Pham | +33 7 85 93 30 17 | nathalie.pham@sanofi.com 
Nina Goworek | +1 908 569 7086 | nina.goworek@sanofi.com  
Thibaud Châtelet | +33 6 80 80 89 90 | thibaud.chatelet@sanofi.com 
Yun Li | +33 6 84 00 90 72 | yun.li3@sanofi.com

WISeSat.Space and SEALSQ Advance Satellite Cybersecurity Hardening as FOSSA Launches New 6U Satellite Aboard SpaceX Falcon 9

This new FOSSASAT-2E27 launch expands opportunities for rigorous in-orbit testing of WISeSat SEALSQ security technologies to strengthen satellite resilience against emerging cyber and quantum threats

Longstanding strategic partnership, supported by successive investments, targets further technology validation across up to six satellite missions as demand for quantum-resistant security is expected to accelerate

GENEVA, Switzerland, October 20, 2026 — WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) (“WISeSat.Space” or “WISeSat”) today announced a new milestone in its secure space infrastructure strategy, following the successful launch and deployment of FOSSASAT-2E27, a new-generation 6U satellite developed and operated by its longstanding strategic partner FOSSA Systems (“FOSSA”), aboard SpaceX’s Falcon 9 Bandwagon-5 mission from Cape Canaveral, Florida.

Equipped with VaultIC secure-element technology from SEALSQ Corp. (Nasdaq: LAES), the spacecraft provides a further opportunity to advance WISeSat’s technology-validation roadmap, building on years of cooperation to integrate hardware-based cybersecurity into satellite systems.

The mission illustrates the value of a strategic industrial relationship established in 2021 through WISeQey Corp’s (SIX/Nasdaq: WQEY) original investment in FOSSA and reinforced by WISeSat’s participation in FOSSA’s latest financing round in June 2026.

Under an extended technical collaboration covering up to six selected FOSSA satellite missions, WISeSat and FOSSA intend to pursue more systematic and demanding in-orbit testing protocols for SEALSQ security technologies, including repeatable functional testing, performance monitoring and analysis under actual space operating conditions.

The collaboration is expected to support the progressive validation of VaultIC secure elements and, subject to technical readiness and integration, the next-generation QS7001 post-quantum secure element. Selected experiments are intended to include six-month in-orbit testing and monitoring periods, generating technical data to inform future satellite security architectures.

Positioning for Growing Post-Quantum Security Requirements

The expanded collaboration comes as governments and critical infrastructure operators prepare for the transition toward quantum-resistant cybersecurity. In particular, U.S. Executive Order 14412, issued on June 22, 2026, establishes an accelerated framework for federal migration to post-quantum cryptography, including requirements scheduled for implementation from 2030 onward.

WISeSat believes that building practical flight heritage and strengthening in-orbit validation today will be important to addressing future requirements for trusted satellite communications, including sovereign, defense and critical-infrastructure applications.

Carlos Moreira, CEO of WISeSat.Space, commented: “Building quantum-resilient space infrastructure requires a clear path from technology development to demonstrated performance in orbit. This planned mission represents the next step in that process by providing another platform to evaluate SEALSQ’s security technologies under real operating conditions. Through our collaboration with FOSSA, we aim to apply what we learn from today’s testing to future satellite systems, while preparing for the integration and validation of next-generation post-quantum security.”

Gwenaël Rouy-Poirier, Group CFO of WISeSat.Space, added: “This launch is a strong illustration of how we intend to execute our strategy: leveraging long-term industrial partnerships and targeted investments to accelerate technology development and validation while maintaining capital discipline. As governments and critical infrastructure operators prepare for the transition to post-quantum security, reinforced by the recent White House Executive Order, we believe that demonstrated performance in orbit will become an increasingly valuable differentiator. Our collaboration with FOSSA allows us to continue building that evidence today, as we prepare for the next generation of WISeSat infrastructure and the commercial opportunities we expect to emerge.”

Julián Fernández, CEO and Co-founder of FOSSA Systems, commented: “Our relationship with WISeSat goes well beyond individual satellite launches. We have worked together for several years to bring advanced semiconductor security technologies into space, and our new 6U platform creates further opportunities to expand that work. With the next phase of our collaboration, we intend to move toward more systematic in-orbit testing and validation, building the technical experience required for increasingly sophisticated secure satellite applications.”

The FOSSASAT-2E27 mission also incorporates software-defined radio capabilities, onboard AI processing and a separate electric-propulsion demonstration, reflecting the technological evolution of FOSSA’s satellite platforms.

The collaboration complements WISeSat’s broader roadmap to develop next-generation, quantum-resilient orbital infrastructure intended to support SEALSQ’s planned Quantum Spatial Orbital Cloud (QSOC) and other secure communications applications.

About FOSSA Systems

FOSSA Systems is a Spain-based aerospace company specializing in small-satellite development, launch and operations, providing space infrastructure for communications and related applications. Visit fossa.systems

About WISeSat.Space

WISeSat.Space Holdings Corp. (Nasdaq: SAIQ) is a space technology company focused on secure satellite communications and related space infrastructure. Its approach combines satellite infrastructure with cybersecurity and digital identity technologies to support trusted communications between connected devices and ground-based systems. WISeSat.Space intends to provide satellite capacity and related space and ground infrastructure that may support SEALSQ’s planned QSOC roadmap. Visit wisesat.space

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements also include, but are not limited to, statements regarding estimation of the listing. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of WISeSat’s management and are not predictions of actual performance. These statements involve risks, uncertainties and other factors that may cause the actual results, levels of activity, performance, or achievements to be materially different from those expressed or implied by these forward-looking statements. Although WISeSat believes that it has a reasonable basis for each forward-looking statement contained in this press release, WISeSat cautions you that these statements are based on a combination of facts and factors currently known and projections of the future, which are inherently uncertain. The forward-looking statements in this press release represent the views of WISeSat as of the date of this press release. Subsequent events and developments may cause those views to change. Except as may be required by law, WISeSat does not undertake any duty to update these forward-looking statements.

CONTACTS

WISeSat:
Carlos Moreira
Chairman & CEO
Tel: +41 22 594 3000
info@wisesat.com

WISeSat Investor Relations:
The Equity Group Inc.
Lena Cati
Tel: +1 212 836-9611
Lena.cati@theequitygroup.com

Transactions during 13 October 2026 – 19 October 2026
On 7 May 2026, Alm. Brand A/S announced a share buy-back program of up to DKK 593 million, as described in company announcement no. 23/2026.

The program is carried out in accordance with the Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052, also referred to as the Safe Harbour Regulations.

The following transactions were made under the share buy-back program 13 October – 19 October 2026:

	Number of shares bought	Average purchase price	Amount (DKK)
Accumulated, last announcement 13 October 2026 14 October 2026 15 October 2026 16 October 2026 19 October 2026	16,272,795 330,000 200,000 311,000 303,000 350,000	16.44 16.77 16.77 16.95 16.97 17.11	267,545,385 5,534,562 3,354,700 5,272,134 5,142,455 5,987,625
Total, 13 October – 19 October 2026	1,494,000	16.93	25,291,477
Accumulated under the program	17,766,795	16.48	292,836,862

With the transactions stated above Alm. Brand A/S holds a total of 50,503,465 own shares, corresponding to 3.59% of the total number of outstanding shares.

Contact
Please direct any questions regarding this announcement to:

Investors and equity analysts:                 

VP, Head of Investor Relations & ESG        
Mads Thinggaard                 
Mobile no, +45 2025 5469                

Attachments

• Alm Brand_Share buyback 13 October – 19 October 2026
• AS 57 2026 – Transactions under share buyback program

October 20, 2026

Advanced reporting and workflow capabilities developed by MediReport are expected to complement Philips’ cardiovascular informatics portfolio and support its evolution toward a more connected, AI-enabled and cloud-ready cardiovascular experience. 

Amsterdam, the Netherlands – October 20, 2026 – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today highlighted how advanced reporting and workflow capabilities developed by MediReport are expected to complement its cardiovascular informatics portfolio and support its broader Integrated Diagnostics vision ahead of Transcatheter Cardiovascular Therapeutics (TCT) 2026.  

Philips brings together expertise in diagnostic and interventional cardiology, image-guided therapy and informatics to support cardiovascular care, from diagnosis through intervention and follow-up. As part of its presence at TCT, Philips will showcase innovations that support clinical confidence, streamline workflows and make meaningful information easier to access, while engaging with customers and clinical leaders on opportunities to better connect diagnostic and interventional care.  

Cardiovascular teams often work across separate imaging, hemodynamic, documentation and reporting systems. This can require repeated data entry and delay access to the complete clinical information needed for procedure reporting, coding and follow-up.  

In Philips’ Future Health Index 2025: Cardiology Snapshot, 79% of cardiac care professionals surveyed reported losing clinical time because patient data was incomplete or inaccessible. Almost half of this group reported losing more than 45 minutes per shift [1]. These findings underline the need to make clinical information easier to capture, access and reuse across the care pathway. 

Following the acquisition of MediReport, Philips expects to strengthen its cardiovascular informatics capabilities. MediReport 360 supports structured cardiovascular documentation and real-time reporting at the point of care, with guided workflows before, during and after procedures. It enables health systems to capture clinical information once and reuse it across physician and nursing reports, coding, registries, analytics, charge capture and follow-up. MediReport’s technologies support cloud and on-premises deployment, with vendor-neutral interfaces to imaging systems, hemodynamic systems and hospital IT.   

This expected enhancement would build on Philips’ existing cardiology informatics portfolio, including Cardiovascular Workspace for image and information management, with cloud deployment available in North America; Ultrasound Workspace for ultrasound review, analysis and reporting; and interventional solutions supporting cath-lab information management and hemodynamic workflows.  

“Clinicians need technology that fits the way they work and gives them more time for patient care”, said Madhuri Sebastian, Business Unit Leader Imaging Informatics at Philips. “The capabilities developed by MediReport complement Philips’ strengths in cardiovascular imaging, hemodynamics and enterprise informatics. Together, they are expected to simplify how information moves across cardiac care, enabling a more connected experience for care teams. This would also support Philips’ longer-term direction towards cloud-ready, AI-enabled cardiovascular and integrated diagnostics workflows.”  

Visit Philips at TCT 2026 to explore innovations in imaging, physiology, procedural guidance and cardiovascular informatics that help care teams access meaningful information and simplify reporting and workflows.

[1] Philips Future Health Index 2025: Cardiology Snapshot — Building trust in AI for cardiac care. 

For further information, please contact:

Name Jayme Maniatis
Philips Global External Relations
Tel.: +16178948368
E-mail: name.here@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in image-guided therapy, diagnostic imaging, ultrasound, monitoring, enterprise informatics and personal health. Philips generated 2025 sales of approximately EUR 18 billion and employs approximately 63,700 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachment

• Philips cardiology informatics at TCT

Recognition highlights company’s FDA-cleared AI technology combining pulmonary nodule detection and diagnosis to aid radiologists in lung cancer diagnosis

SAN FRANCISCO, CA and SOPHIA ANTIPOLIS, France, Oct. 20, 2026 (GLOBE NEWSWIRE) — Eyonis Inc., a Median Technologies company focused on applying artificial intelligence to the early detection and diagnosis of cancer, today announced that it has been named a Rising Star finalist in the Cancer, Screening & Early Detection category of the 2026 Digital Health Hub Foundation Digital Health & AI Awards.

Selected from a field of more than 1,300 submissions, the finalists represent companies developing technologies with the potential to improve healthcare. The prestigious annual awards recognize innovation across digital health, including cancer screening, diagnostics, disease prevention and care delivery.

Eyonis was recognized for its work advancing AI-powered lung cancer screening, including the development of eyonis® LCS, the first FDA-cleared AI-powered solution to both detect pulmonary nodules and assess their likelihood of malignancy on low-dose CT scans to aid radiologists in lung cancer diagnosis.

The recognition comes as healthcare providers look for ways to expand lung cancer screening while improving the accuracy of screening results. Low-dose CT scans can reveal potentially cancerous nodules before symptoms develop, but finding a nodule is only the beginning. Radiologists working with pulmonologists must also assess a nodule’s likelihood of malignancy to help decide whether it needs further diagnostic work-up or prolonged surveillance, which can lead to patient anxiety and difficult decisions about whether to recommend a potentially dangerous invasive biopsy.

eyonis® LCS addresses both stages of that process, supporting the detection of suspicious pulmonary nodules and the assessment of their likelihood of malignancy from low-dose CT examinations. By bringing detection and diagnosis into a single lung cancer screening workflow for the first time, the technology addresses one of the most significant challenges in lung cancer care—helping clinicians identify cancer earlier with greater diagnostic confidence.

“Lung cancer screening has enormous potential to save lives, but detecting more nodules doesn’t necessarily mean finding more cancer,” said Oran Muduroglu, President of Eyonis. “Clinicians need to know which findings are most concerning and which patients may need additional evaluation. We developed eyonis LCS to help answer that question. Being named a Rising Star finalist recognizes our team’s work to move beyond detection and give clinicians more meaningful diagnostic information.”

eyonis® LCS has demonstrated[i] sensitivity of 93.3%, specificity of 92.4%, and a 99.9% negative predictive value.  With eyonis® LCS supporting, this translates into radiologists improving sensitivity by 13 percentage points and specificity by 16 percentage points, while reducing false negatives by 66% and false positives by 68%.[ii] [iii]

These findings suggest that combining radiologists’ clinical expertise with AI assistance offers the potential to match or even surpass the software’s standalone diagnostic performance. The results also demonstrate the software’s ability to aid clinicians in identifying patients with lung cancer while minimizing false positive results that may lead to unnecessary and costly additional imaging or invasive procedures.

The winners of the 2026 Digital Health & AI Awards will be announced Nov. 16 at the 2026 HLTH conference in Las Vegas.

About Eyonis

Eyonis, a Median Technologies company, markets a suite of AI-powered Software as a Medical Device (SaMD) designed to improve the early detection and diagnosis of cancer. Its flagship product, eyonis® LCS, analyzes low-dose CT examinations to support both the detection of suspicious lung nodules and the assessment of their likelihood of malignancy within the lung cancer screening workflow. eyonis® LCS received FDA clearance in the United States in February 2026 and CE marking in Europe in July 2026. To learn more, visit https://eyonis.ai.

About Median Technologies

Median Technologies provides AI-powered medical imaging solutions for cancer diagnosis, treatment and drug development. The company operates through two businesses: Eyonis, which develops AI-powered Software as a Medical Device for cancer detection and diagnosis, and iCRO, which provides imaging services for oncology clinical trials. Headquartered in France with operations in the United States and China, Median Technologies is listed on Euronext Growth Paris under the ticker ALMDT. To learn more, visit https://mediantechnologies.com/ 

---

[i] Manufacturer Values, Median Technologies data on file.

[ii] Estimated from Jonas DE, et al. JAMA. 2021 Mar 9;325(10):971-987

[iii] RELIVE MRMC (Multi-Reader Multi-Case) Study, ClinicalTrials.gov ID: NCT06751576.

Attachment

• Digital Health & AI Award Badge

CONTACT: Todd Stein
eyonis
5104170612
todd@toddsteincommunications.com

WUHU, China, Oct. 20, 2026 (GLOBE NEWSWIRE) — From October 19 to 23, the 2026 Chery International User Summit is bringing together users, media representatives and ecosystem partners from around the world in Wuhu. Under the theme “HIGH TECH FOR OUR FUTURE LIFE”, the summit will explore the future of intelligent, low-carbon and sustainable mobility and lifestyles.

During the summit, Chery Auto will showcase advances in green energy manufacturing, intelligent charging and Robotaxi technology, while AiMOGA Robotics will demonstrate intelligent services through live interactions. From charging and autonomous driving to robotics, technology is making everyday life more convenient. As mobility expectations evolve beyond reaching a destination, comfort and quality of life are gaining importance. Through interactive experiences and global user exchanges, the summit will explore how technology can enrich daily life and connect brands with users.

As Chery Auto’s Premium NEV brand, LEPAS responds to users’ expectations for distinctive design, intelligent convenience and comfort through its three core pillars: Leopard Aesthetics, Elegant Technology and Exquisite Space. As LEPAS launches and delivers its NEV lineup worldwide, users are experiencing these pillars firsthand. From first impressions of a vehicle’s exterior and cabin in the showroom to daily commutes and longer journeys, users are discovering what “Drive Your Elegance” means through everyday driving experiences.

As these experiences reach different markets, local tastes, road conditions and ways of life shape different perspectives on elegance. The summit brings these experiences and personal stories together in Wuhu, giving LEPAS and its global users an opportunity to exchange ideas and collaborate in person.

On October 18, LEPAS launched its inaugural Global Elegant Lifestyle Week. The first LEPAS owners, partners, industry media and Global Elegant Lifestyle Partners from different regions began arriving in Wuhu for the event, held under the theme “TOGETHER IN ELEGANCE.”

During the week, participants will explore elegance through four dimensions: design, technology, driving and lifestyle. They will share driving experiences, exchange cultural perspectives on aesthetics and explore elegant living across cultures with LEPAS. Their feedback will inform LEPAS’s product, service and brand development.

Throughout the week, LEPAS will bring elegance to life through shared experiences. The LEPAS Global Journey of Elegant Driving and practical demonstrations will showcase composed driving on real roads and the convenience of intelligent technology in everyday situations. The LEPAS All-New Concept Car will offer a vision of future mobility design, while Global Elegance Night will bring together different cultures and personal stories.

Beyond driving experiences, LEPAS seeks to build deeper connections with users and partners worldwide through shared ideas and collaboration. The relationships formed in Wuhu will extend beyond the event, bringing LEPAS’s vision of elegance into everyday life.

About LEPAS

LEPAS is Chery Auto’s Premium NEV brand, dedicated to creating elegant mobility experiences for users worldwide. Committed to becoming the Preferred Brand for Elegant Mobility Life, LEPAS brings together Leopard Aesthetics, Elegant Technology, and Exquisite Space – transforming elegance into a driving experience you can see, feel, and trust. Supported by a growing global dealer network of more than 500 sales and service outlets, LEPAS is expanding its international footprint through localized operations, delivering products and experiences tailored to users across global markets.

Media Contact

Company Name: LEPAS International

Contact Person: Vincy Wang

E-mail: GlobalPR@lepasinternational.com

Company Official Website: https://lepasinternational.com/

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/d3ec1b83-abec-42d9-ac19-72c1a8f53777
https://www.globenewswire.com/NewsRoom/AttachmentNg/d660e395-9de2-4df6-9d9e-f9fc5a14429c